Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240027/S005

SpineSeal Spine Sealant

Pramand, LLC · Decision date Apr 1, 2026

FDA DECISIONP240027/S005

What did the FDA decide?

FDA records P240027/S005 as a supplement to PMA P240027, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 1, 2026.

FDA approval order statement

a change to remove visible particulates prior to final packaging
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Apr 1, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P240027/S005
Regulatory pathway
PMA supplement
Applicant
Pramand, LLC
Product code
NQR
Decision code
OK30
Decision date
Apr 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sealant, dural.

Applicant
Pramand, LLC
Product code
NQR
FDA device class
3

For the original device and its historical approval scope, see PMA P240027. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240027 · Original PMA

    SpineSeal Spine Sealant

  2. P240027/S004 · Related supplement

    SpineSeal Spine Sealant

  3. P240027/S005 received

    Application receipt date recorded by FDA.

  4. P240027/S005 · FDA decision

    30-Day Notice

  5. P240027/S006 · Related supplement

    SpineSeal Spine Sealant

  6. P240027/S007 · Related supplement

    SpineSeal Spine Sealant

Timeline entries are records held by MedtechLedger for P240027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240027

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA approvalFeb 14, 2025FDA
Pramand, LLCPMA supplementNov 7, 2025FDA
Pramand, LLCPMA supplementAug 31, 2026FDA
Pramand, LLCPMA supplementSep 11, 2026FDA

Explore the linked device profile

Other records with product code NQR

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA supplementOct 1, 2026FDA
Pramand, LLCPMA supplementAug 5, 2026FDA
Stryker Leibinger GmbH & Co. KGPMA supplementJul 15, 2026FDA
Pramand, LLCPMA supplementApr 1, 2026FDA
Integra LifeSciences CorporationPMA supplementFeb 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Pramand, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., Suite 210, Bedford, MA, 02420

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records